Trends Over Time for Adolescents Enrolling in HIV Care in Kenya, Tanzania, and Uganda From 2001–2014 by Apondi, Edith et al.
Trends Over Time for Adolescents Enrolling in HIV Care 
in Kenya, Tanzania, and Uganda from 2001-2014 
Edith Apondi, MBChB, Mmed,*† John M. Humphrey, MD, MS,*†‡ Edwin Sang, MS,† Ann 
Mwangi, PhD,§ Alfred Keter, MSc, BSc,† Beverly S. Musick, MS,†|| Fred K. Nalugoda, B. Stat, 
MHSc, PhD,¶ John Ssali, MD,# Elizabeth Bukusi, MBChB, MD, MPH, PhD,**†† Constantin T 
Yiannoutsos, PhD,‡‡ Kara Wools-Kaloustian, MD, MS,†‡ Samuel Ayaya, MBChB, Mmed*† 
* Department of Child Health and Paediatrics, School of Medicine, College of Health Sciences,
Moi University, Eldoret, Kenya
† Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya 
‡ Department of Medicine, Indiana University School of Medicine, Indianapolis, United States 
§ Department of Behavioral Sciences, Moi University College of Health Sciences, Eldoret,
Kenya
|| Department of Biostatistics, Indiana University School of Medicine, Indianapolis, United 
States 
¶ Rakai Health Sciences Program, Kalisizo-Station, Kalisizo, Rakai, Uganda 
# Masaka Regional Referral Hospital, AHF-Uganda Cares Masaka, Uganda 
** Family Aids Care and Education Services (FACES), a collaboration between the Kenya 
Medical Research Institute and the University of California San Francisco, Kisumu, Kenya 
†† Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya 
‡‡ Department of Biostatistics, Indiana University Fairbanks School of Public Health, 
Indianapolis, United States 
AC
CE
PT
ED
JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print
DOI: 10.1097/QAI.0000000000001796
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Apondi, E., Humphrey, J. M., Sang, E., Mwangi, A., Keter, A., Musick, B. S., … Ayaya, S. (2018). Trends Over Time 
for Adolescents Enrolling in HIV Care in Kenya, Tanzania, and Uganda from 2001-2014. JAIDS Journal of Acquired 
Immune Deficiency Syndromes, Publish Ahead of Print. https://doi.org/10.1097/QAI.0000000000001796
 2 
E.A. and J.M.H. contributed equally to the work. 
 
Correspondence:  Dr. John Humphrey 
545 Barnhill Drive, EH 421  
Indianapolis, IN 46202 
Phone: +1 317-274-8115 
Fax: +1 317-274-1587 
humphrjm@iu.edu  
 
Presented at: 9th IAS Conference on HIV Science. 2017 July 23-26; Paris, France 
 
Conflicts of Interest and Source of Funding: All authors declare no conflicts of interest. Research 
reported in this publication was supported by the National Institute Of Allergy And Infectious 
Diseases (NIAID), Eunice Kennedy Shriver National Institute Of Child Health & Human 
Development (NICHD), National Institute On Drug Abuse (NIDA), National Cancer Institute 
(NCI), and the National Institute of Mental Health (NIMH), in accordance with the regulatory 
requirements of the National Institutes of Health under Award Number U01AI069911East Africa 
IeDEA Consortium. The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of Health. 
 
Running head: Adolescents Enrolling in HIV Care  
 
AC
CE
PT
ED
Copyright  2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 3 
Abstract 
Background: The data needed to understand the characteristics and outcomes, over time, of 
adolescents enrolling in HIV care in East Africa are limited. 
 
Setting: Six HIV care programs in Kenya, Tanzania, and Uganda. 
 
Methods: This retrospective cohort study included individuals enrolling in HIV care as 
younger adolescents (10-14 years) and older adolescents (15-19 years) from 2001-2014. 
Descriptive statistics were used to compare groups at enrollment and antiretroviral therapy 
(ART) initiation over time. The proportion of adolescents was compared to the total number of 
individuals ≥10 years of age enrolling over time. Competing-risk analysis was used to estimate 
12-month attrition post-enrollment/pre-ART initiation; post-ART attrition was estimated by 
Kaplan-Meier method.   
 
Results: A total of 6,344 adolescents enrolled between 2001-2014. The proportion of 
adolescents enrolling among all individuals increased from 2.5% (2001-2004) to 3.9% (2013-
2014, P < 0.0001). At enrollment, median CD4 counts in 2001-2004 compared to 2013-2014 
increased for younger (188 vs. 379 cells/mm3, P < 0.0001) and older (225 vs. 427 cells/mm3, P < 
0.0001) adolescents. At ART initiation, CD4 counts increased for younger (140 vs. 233 
cells/mm3, P < 0.0001) and older (64 vs. 323 cells/mm3, P < 0.0001) adolescents. Twelve-month 
attrition also increased for all adolescents both post-enrollment/pre-ART initiation (4.7% vs. 
12.0%, P < 0.001) and post-ART initiation (18.7% vs. 31.2%, P < 0.001).  
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Conclusions: Expanding HIV services and ART coverage was likely associated with earlier 
adolescent enrollment and ART initiation but also with higher attrition rates before and after 
ART initiation. Interventions are needed to promote retention in care among adolescents. 
 
Key words: HIV; adolescents; antiretroviral therapy; East Africa; retention 
 
INTRODUCTION 
 
Adolescents living with HIV are a priority population in addressing the global HIV epidemic.1,2 
The major burden of HIV among adolescents exists in sub-Saharan Africa, where 85% of the 
estimated 2 million global HIV-infected adolescents live, and where 92% of global AIDS-related 
adolescent deaths occur.3-5 Although new HIV infections and AIDS-related deaths have declined 
overall in sub-Saharan Africa, HIV remains the leading cause of death among adolescents 10-19 
years of age in the region.3,6 Furthermore, the World Health Organization estimated a 50% 
increase in the incidence of AIDS-related deaths among adolescents from 2005-2012, compared 
to a 32% decrease among other age groups.4,7 Despite the broad scale-up of HIV services that 
includes expanded antiretroviral therapy (ART) coverage and eligibility that occurred over this 
timeframe, few studies describe how the characteristics of adolescents enrolling in HIV care and 
initiating ART has changed over the years.6 
 
Understanding these characteristics is important, as adolescents face multiple challenges in 
navigating the HIV care and treatment cascade. Limited awareness of HIV infection, inadequate 
access to testing and counseling services, and low uptake of these services lead to delayed care 
entry and more advanced disease stage at enrollment in care.1,8-11 Multiple studies in sub-Saharan 
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Africa have reported higher attrition for adolescents both before and after ART initiation when 
compared to adults, and poor adherence to ART and attrition have both been associated with 
worse virologic outcomes and higher mortality compared to adults.11-23 Many of these studies 
report aggregate data or are limited by small sample sizes.4 As such, they do not allow us to 
address the distinct developmental and social differences between younger and older adolescents, 
who may have different modes of HIV acquisition and risks of adverse outcomes. Moreover, 
many studies are cross-sectional and limited in their ability to extrapolate epidemiologic trends 
to evaluate and contextualize public health interventions, or sample from few geographic 
locations with potentially limited generalizability.4  
 
As of 2014, Kenya, Tanzania, and Uganda together accounted for 33% of HIV-infected 
adolescents aged 10-19 and 31% of AIDS-related adolescent deaths in Eastern and Southern 
Africa.24 The population of HIV-infected adolescents in these and other global regions is 
expected to grow over the coming years, given the increasing survival of perinatally-infected 
children, the contribution of new sexually-transmitted infections, and the projected increase in 
the absolute number of adolescents in living in low-income countries.4,25 Achieving the Joint 
United Nations Programme on HIV/AIDS 90-90-90 targets for this vulnerable population will 
require robust data concerning the epidemiologic patterns of adolescents enrolling in HIV care 
and initiating ART.6,26 The objective of this study is to understand the characteristics and 
outcomes over time of adolescents enrolling in HIV care and initiating ART in Kenya, Tanzania, 
and Uganda using data from the East Africa (EA) International Epidemiology Databases to 
Evaluate AIDS (IeDEA) Consortium. 
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METHODS 
 
Study design  
This retrospective cohort utilized data of prospectively enrolled HIV-infected adolescents 
attending HIV care programs affiliated with the EA-IeDEA Consortium. The study was 
approved under the EA-IeDEA by the Indiana University IRB and all local regulatory bodies  
affiliated with each participating site. Patient-level consent was waived by all regulatory bodies 
because the data were collected as part of routine clinical care and were de-identified prior to 
data transfer and analysis. 
 
Study setting 
This study was conducted at six HIV care programs in Kenya, Tanzania, and Uganda that 
participate in EA-IeDEA, an NIH-funded consortium that pools and harmonizes patient data 
collected in the context of routine care. Descriptions of the study sites can be found 
elsewhere.27,28 All facilities provided standard-of-care HIV treatment services as per their 
respective local and national guidelines. None of the facilities during the period of study offered 
Adolescent Clinics. With the exception of Moi Teaching and Referral Hospital at the AMPATH 
program in Kenya, all children were seen in the same clinic as adults, though at times there was a 
dedicated clinic day for children when a consultant might be present to support the regular 
providers, care was not transitioned. At this clinic, adolescents were commonly seen in the 
pediatric clinic into their 20s. The study population included all adolescents who were between 
10 and 19 years of age, inclusive, at the time of enrollment in HIV care at one of the 
participating programs between 2001 and 2014.  
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Data management 
At each facility, demographic and clinical data were collected on paper-based forms completed 
by clinicians during the course of routine clinical care. Forms were then transcribed into the local 
electronic medical record (EMR) system by trained data entry clerks. Data quality assessments 
were performed according to local protocols for each facility. Data were transferred biannually to 
the IeDEA-EA Regional Data Center where they were merged and additional data quality 
assessments were undertaken before data were submitted for analysis. 
 
Data Analysis 
Adolescence was defined as ages 10-19 to be consistent with the World Health Organization 
(WHO) and United Nations definition of adolescence.3,29 Adolescents were stratified into two 
groups based on age at the time of enrollment in HIV care: younger adolescents (10-14 years) 
and older adolescents (15-19 years). Patient-level, independent variables included: 1) 
demographic characteristics: sex, age, and pregnancy status at enrollment, and 2) clinical 
characteristics: WHO clinical stage at enrollment and at ART initiation, CD4 count at 
enrollment and at ART initiation, receipt of pneumocystis pneumonia (PCP) prophylaxis or 
isoniazid prophylaxis for tuberculosis (IPT). For all post-enrollment variables, the follow-up 
time was constructed such that younger adolescents were censored upon reaching age 15, and 
older adolescents were censored on their 20th birthday. Outcome variables included incident 
pregnancy and TB diagnosis, which excluded prevalent pregnancy and TB cases and were 
reported in person-year incidence rates in order to account for differences in observation time 
between adolescents in each group. The first available WHO stage within 90 days after 
enrollment was recorded as the WHO stage at enrollment. If no WHO stage was given within 
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this window and the next available WHO stage was stage 1, then the WHO stage at enrollment 
was assumed to be stage 1. Subjects with no WHO stage within the 90-day window and no WHO 
stage 1 beyond this window were categorized as having missing WHO stage at enrollment. The 
maximum WHO stage prior to ART initiation was taken to be the WHO stage at ART initiation. 
If no stage was available prior to ART initiation, the first stage within 60 days following ART 
initiation was used. If no WHO stage was given within this 60-day window and the next 
available was stage 1, then the WHO stage was assumed to be stage 1. Otherwise, WHO stage at 
ART initiation was recorded as missing. 
 
In order to assess the changes in characteristics and retention for younger and older adolescents 
at enrollment and ART initiation over time, the study timeframe was divided into four 
enrollment periods: 2001-2004, 2005-2009, 2010-2012, and 2013-2014. The first period 
occurred before the introduction of the United States President’s Emergency Plan for AIDS 
Relief (PEPFAR) program, while the remaining periods align with the WHO guideline changes 
for ART eligibility.30,31 The characteristics of younger and older adolescents enrolling within 
each of these periods were summarized with standard descriptive analyses. The proportion of 
enrolling adolescents was compared to the total number of individuals ≥ 10 years of age 
enrolling during each period. The Cochran-Armitage linear trend test was used for categorical 
variables to assess the presence of association and detect trends across periods for younger and 
older adolescents; the Kruskal-Wallis test was used for continuous variables. All P values were 
two-tailed with a value < 0.05 considered statistically significant. 
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Program attrition at 12 months following enrollment but prior to ART initiation, and at 12 
months following ART initiation, were analyzed in each enrollment period. For this analysis, 
younger adolescents who reached their 15th birthday and older adolescents who reached their 
20th birthday but who had not attained 12 months of follow-up were not censored at their date of 
birth. Attrition was defined as the composite outcome of death and loss to follow-up (LTFU). 
LTFU was defined as having no clinic visits for 90 days after the last scheduled clinic 
appointment and not having been recorded as dead or transferred out before the 12-month 
endpoint.27 Competing-risk estimation was used to estimate attrition incidence following 
enrollment but prior to ART initiation, where ART initiation was treated as a competing risk.  
Cumulative incidence of attrition was calculated by the Aalen-Johansen estimator. Attrition after 
ART initiation was calculated using the Kaplan-Meier method. Cumulative incidence of attrition 
was estimated as one minus the Kaplan Meier estimate of the probability of retention. 
Cumulative incidences were compared between groups using the Gray test.32 In both cases, 95% 
confidence intervals were produced by these methods. Landmark values of attrition at 12 months 
following enrollment and ART initiation, with attendant 95% confidence intervals, were also 
produced. Follow-up time was determined by the Kaplan-Meier method with end of follow-up 
being the event of interest and program attrition considered a censoring event.  
 
RESULTS 
 
Characteristics at enrollment and ART initiation  
A total of 6,344 adolescents aged 10-19 years were enrolled into care from November 27, 2001 
through December 10, 2014 (Table 1). The total number of adolescents enrolled across programs 
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ranged from 142 adolescents (2.2% of total cohort) in Rakai, Uganda, to 3,845 adolescents 
(60.6% of total cohort) at AMPATH, Kenya. Overall, 3,241 (51.1%) were younger adolescents, 
and younger adolescent enrollment exceeded older adolescent enrollment in over half of the 
facilities. Two-thirds (67.2%) of all adolescents were female, with girls accounting for 55.4% of 
younger and 79.5% of older adolescents. The prevalence of tuberculosis at enrollment was 3.5% 
for younger and 1.4% for older adolescents. Among those with available WHO stage at 
enrollment, the majority (71.2%) had WHO stage 1 or 2, including 63.0% of younger and 78.9% 
of older adolescents. Among those with available WHO stage at ART initiation, 46.2% and 
64.2% of younger and older adolescents, respectively, had WHO stage 1 or 2 at ART initiation.  
 
Clinical events while enrolled  
The median follow-up period for younger adolescents was 5.0 years (95% CI 4.6-5.4) and 2.1 
years (95% CI 1.9-2.3) for older adolescents estimated by Kaplan-Meier analysis. The incidence 
of first pregnancy following enrollment was 6 cases per 100,000 person-years for younger and 
100 per 100,000 person-years for older female adolescents. The incidence of tuberculosis was 28 
and 12 cases per 100,000 person-years for younger and older adolescents, respectively.  
 
Characteristics over time 
From 2001 to 2014, the proportion of adolescents among all individuals ≥ 10 years of age 
enrolling at the study facilities increased from 2.5% in 2001-2004 to 3.9% in 2013-2014 (Figure 
1; P < 0.0001). During the same period, the proportion of older adolescents enrolling into care 
increased from 0.9% to 2.6% (P < 0.0001). The proportion of females also increased over time 
for younger (47.1% to 60.8%, P = 0.003) and older (70.7% to 82.7%, P = 0.001) adolescents 
(Table 2). The percentage of younger and older adolescents who received PCP prophylaxis 
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increased over time, from 83.0% to 98.3% for younger (P < 0.0001) and 56.1% to 99.9% for 
older (P < 0.0001) adolescents from 2001-2004 to 2013-2014, respectively. Over the same 
periods, the percentage who received IPT decreased for younger (10.5% to 2.6%, P < 0.0001) 
and older (29.3% to 3.6%, P < 0.0001) adolescents. 
 
Overall, both younger and older adolescents had less advanced HIV disease at enrollment and at 
ART initiation in more recent time periods (Table 2 and Figure 2). At enrollment, median CD4 
counts increased for younger adolescents from 188 cells/mm3 in 2001-2004 to 379 cells/mm3 in 
2013-2014 (P < 0.0001), and also increased among older adolescents, from 225 cells/mm3 to 427 
cells/mm3 (P < 0.0001) over the same periods. At ART initiation, median CD4 counts also 
increased for younger adolescents (140 vs. 233 cells/mm3, P < 0.0001) and older adolescents (64 
vs. 323 cells/mm3, P < 0.0001) over these periods. The proportions of younger adolescents, 
among the various enrollment periods, with missing WHO stage ranged from 29.0-70.2% at 
enrollment and 21.6-73.0% at ART initiation across periods (Table 2). For older adolescents, the 
proportions with missing WHO stage ranged from 23.4-36.6% at enrollment and 22.6-33.3% at 
ART initiation. Statistical analysis for WHO stage differences between groups and over time was 
not performed given the high proportion of missing data.  
 
The cumulative incidence estimates of 12-month attrition after enrollment/pre-ART initiation 
significantly increased over time among all adolescents, from 2.6% in 2001-2004 to 8.7% in 
2013-2014 (P < 0.001; Table 3). Following ART initiation, 12-month attrition among all 
adolescents also increased over the same periods, from 18.7% to 31.2% (P < 0.001). Attrition 
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estimates after enrollment/pre-ART initiation and following ART initiation were significantly 
higher for older compared to younger adolescents in all periods except 2013-2014. 
 
DISCUSSION 
 
This study presents the trends over time for adolescents enrolling in HIV care and initiating ART 
at HIV care programs in Kenya, Tanzania, and Uganda. We found that the proportion of older 
adolescents enrolling among all enrollees ≥ 10 years of age significantly increased from 0.9% in 
2001-2004 to 2.6% in 2013-2014. Although adolescents accounted for a low proportion of 
individuals ≥ 10 years of age enrolling overall, the proportion of older adolescents increased 
nearly threefold over the study timeframe, while the proportion of younger adolescents was 
stable or slightly declined over the same periods. This finding highlights the importance of 
disaggregating adolescent data by age to better understand programmatic and epidemiologic 
trends in the population of adolescents living with HIV. Ongoing tracking of age and sex-
disaggregated enrollment data for adolescents in East Africa will be needed to contextualize the 
potential impact of HIV prevalence-modifying influences in the region (e.g. prevention of 
mother-to-child transmission [PMTCT] program expansion, increasing HIV knowledge and 
prevention behaviors, increasing HIV testing and counseling programs).24  
 
Our study also suggests that the proportion of adolescents enrolling in care and initiating ART 
with advanced HIV disease has decreased markedly over time. It has been reported elsewhere 
that progressive decentralization and expansion of HIV testing and counseling, including home-
based testing and enrollment via PMTCT services, have likely contributed to earlier enrollment 
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of adolescents.8,33-35 In another EA-IeDEA analysis, pregnant women ≥ 13 years of age were 
found to comprise an increasing proportion of those initiating ART from 2004-2014, even prior 
to the expansion of ART eligibility through Option B+.36 However, overall decreases in the 
proportion of individuals starting treatment with WHO stage 3/4 disease over time were 
primarily attributable to non-pregnant women and men rather than pregnant women. Earlier ART 
initiation may also reflect earlier enrollment, as well as higher national CD4-based ART 
eligibility thresholds, better treatment of sicker individuals, and increasing care capacity and 
ART access for HIV programs in the region over time.11,35,37,38 Our data, which are largely 
descriptive in nature, cannot directly address these issues, but the observed trends are consistent 
with the aforementioned studies and add to the growing volume of studies showing the 
association of ART scale-up and contemporary patient trends in our region.39 The increase in 
median CD4 count at enrollment further suggests that horizontally infected adolescents are 
seeking care earlier, which may also be contributing to the increasing enrollment of older 
adolescents. This may also include younger adolescents with horizontally acquired infections, as 
population data from Kenya, Tanzania, and Uganda indicate 9-12% of boys and 12-22% of girls 
have had sex before the age of 15.5 Importantly, median CD4 counts at ART initiation 
throughout our study remained below 350 cells/µl for younger and older adolescents despite the 
2009 recommendation that ART be initiated at this CD4 threshold irrespective of clinical 
symptoms.31 Continued increases in CD4 counts at enrollment and ART initiation are anticipated 
in the future with broader HIV testing and adoption of universal treatment guidelines.  AC
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Finally, we found that attrition significantly increased over time for all adolescents and was 
nearly twice as high among older compared to younger adolescents in all periods except 2013-
2014. This findings emphasize the importance of addressing adolescent attrition, particularly 
among older adolescents, within HIV programs in our region. Notably, attrition prior to ART 
initiation markedly increased among younger and older adolescents in 2005-2009 compared to 
2001-2004. This coincides with the major expansion of HIV care and treatment capacity in the 
region under the US President's Emergency Plan for AIDS Relief (PEPFAR) after 2005. During 
the ensuing increase in the number of adolescents enrolling in HIV care, programs may not have 
been adequately equipped to manage attrition prior to ART initiation, when the CD4 criterion for 
ART initiation was ≤ 350 cells/ mm3. Changing programmatic or facility characteristics 
(including implementation of pediatric-focused clinics and service delivery), treatment 
guidelines, poor patient tracing amidst increasing adolescent enrollment, or changing 
demographic and clinical characteristics (e.g. HIV disease stage) of adolescents enrolling in HIV 
care, may also account for the estimated increases in attrition over time in our study. That 
attrition was higher for older compared to younger adolescents is consistent with other studies, 
and likely reflects the increased autonomy experienced by older adolescents during their 
transition to adulthood as well as differences in care and treatment approaches by providers as 
adolescents age.11,21-23,34 Within this study, we are unable to address the issues surrounding 
transition during adolescents because the clinics represented during the study period did not have 
standardized practices for transition. However, we have an ongoing study of transitioning and 
will be able to address this in a future paper. Transition of care for adolescents and youth has 
emerged as a key issue that involves increasing roles and responsibilities for adolescents as they 
navigate developmental and psychosocial changes, as well as changes in healthcare providers 
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and care structure.40 Data to understand transition outcomes and optimal models of transition are 
limited in sub-Saharan Africa. Adolescent-focused services and staff that include peer and 
psychosocial support are likely required, and existing transition policies need to be 
implemented.40-44 Reducing attrition among adolescents enrolling in HIV care in our region will 
also require a better understanding of LTFU (i.e. as un-identified mortality, silent transfer, or 
complete disengagement from care), as well as a deeper grasp of the individual, social, and 
facility-level factors that influence attrition.27,43  
 
Our data have several strengths but also significant limitations. A strength of this study is its 
longitudinal focus on adolescent care across multiple high- and low-volume facilities serving 
adolescents in East Africa. Our study provides a broad picture of the evolving HIV epidemic 
among adolescents that may serve as a benchmark against which future research can be 
evaluated. The use of routine program data to understand adolescent characteristics at enrollment 
and post-ART initiation phases of care is both a strength, as our data is likely to reflect typical 
care environments in East Africa, and limitation, as reliance on routine program data resulted in 
missing WHO stage in a high proportion of adolescents. This limitation is consistent with other 
adolescent studies utilizing routinely collected data in sub-Saharan Africa.11,21,23,35 Our study also 
included a limited number of HIV facilities across East Africa which may not be generalizable to 
the region as a whole, particularly given the variability in resources and HIV services that exist 
within and between countries. Finally, our attrition results may have been affected by 
overestimation of LTFU (e.g. due to undocumented transfer).45 Although, LTFU among patients 
with generally less advanced HIV disease suggests that most of the program attrition is caused 
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by disengagement from care rather than death. This limitation underscores the importance of 
understanding the causes of LTFU in order to accurately understand program attrition.46  
 
Finally, it is important to recognize that our findings are not disaggregated by gender, and there 
remains a paucity of gender-disaggregated retention data and for adolescents in sub-Saharan 
Africa.47-50 Two studies did not identify gender differences in adolescent LTFU, while one in 
South Africa identified higher retention among males attending adolescent-friendly clinics.51-53 
This contrasts with multiple studies among adults in sub-Saharan Africa that have found higher 
LTFU among males compared to females.54-56 Given the significant developmental and 
psychosocial changes that occur during adolescence, which can affect males and females 
differently, research in this area is critically needed. Stigma, disclosure, depression, and other 
stressors may be experienced and coped with differently by each gender.57-59 Pregnancy may also 
jeopardize retention among female adolescents. In a related EA-IeDEA study, the risk of LTFU 
was nearly twice as high for pregnant compared to non-pregnant female adolescents.60 Moreover, 
attrition during PMTCT follow-up is alarmingly common.57,61 Future studies are needed to 
explore the gender-specific factors that influence retention and adherence, both to more sharply 
define and track the adolescent HIV epidemic, and to develop more appropriately targeted 
interventions in program design, policy, and advocacy for adolescents. 
 
CONCLUSIONS  
Earlier enrollment and ART initiation occurred over time for adolescents in East Africa, likely 
influenced by the scale-up of HIV testing, ART coverage, and national guidelines recommending 
earlier ART initiation in the region. However, attrition also increased over time for younger and 
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older adolescents, emphasizing the need for additional efforts to address and define the factors 
and interventions that promote retention among adolescents, particularly for those ≥ 15 years of 
age. Future longitudinal analyses will be needed to track the evolving HIV epidemic among 
adolescents in East Africa.  
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FIGURE CAPTIONS 
 
Figure 1. Proportion of adolescents among all individuals ≥ 10 years of age enrolling at the 
study facilities from 2001-2014.*† 
 
Footnotes:  
*
 The total number of individuals ≥ 10 years of age enrolling at the study facilities during each 
period was: 2001-2004 (n=9,320); 2005-2009 (n=110,488); 2010-2012 (n=62,838); 2013-2014 
(n=27,223).  
†
 Proportions were significantly different from one another across periods for younger (P < 
0.0001) and older (P < 0.0001) adolescents. 
 
  
 
 
Figure 2. Median CD4 count for younger, older, and total (labeled) adolescents at enrollment 
and ART initiation across periods. All values were significantly different from one another 
across periods (P < 0.0001). 
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TABLES 
 
Table 1. Characteristics at enrollment at study facilities in Kenya, Tanzania, and Uganda from 2001-2014. 
 
AMPATH, Academic Model Providing Access to Healthcare; ART, antiretroviral therapy; FACES, Family AIDS Care 
and Education Services; WHO, World Health Organization 
*
 Percentage expressed among female adolescent population only. 
†
 A total of 4,520 adolescents initiated ART.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Total 
n (%) 
n=6344 
Younger adolescents  
10-14 years, n (%) 
n=3241 
Older adolescents 
15-19 years, n (%) 
n=3103 
East African IeDEA site     
  AMPATH, Kenya 3845 (60.6) 2266 (69.9) 1579 (50.9) 
  FACES, Kenya 1198 (18.9) 270 (8.3) 928 (29.9) 
  Morogoro, Tanzania 285 (4.5) 188 (5.8) 97 (3.1) 
  Tumbi, Tanzania 221 (3.5) 125 (3.9) 96 (3.1) 
  Masaka, Uganda 653 (10.3) 312 (9.6) 341 (11.0) 
  Rakai, Uganda 142 (2.2) 80 (2.5) 62 (2.0) 
Sex    
  Male 2082 (32.8) 1447 (44.7) 635 (20.5) 
  Female 4262 (67.2) 1794 (55.4) 2468 (79.5) 
Pregnant at enrollment* 534 (12.5) 15 (0.8) 519 (21.0) 
Tuberculosis at enrollment 156 (2.5) 114 (3.5) 42 (1.4) 
WHO stage at enrollment    
    Stage 1 and 2 3077 (48.5) 1320 (40.7) 1757 (56.6) 
    Stage 3 and 4 1244 (19.6) 775 (23.9) 469 (15.1) 
    Missing 2023 (31.9) 1146 (35.4) 877 (28.3) 
WHO stage at ART initiation†    
    Stage 1 and 2 1803 (39.9) 842 (32.9) 961 (49.1) 
    Stage 3 and 4 1518 (33.6) 981 (38.3) 537 (27.4) 
    Missing 1199 (26.5) 739 (28.8) 460 (23.5) 
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Table 2. Characteristics of adolescents enrolling at study facilities in Kenya, Tanzania, and Uganda over four time 
periods between 2001 and 2014. 
 
Characteristic Period of Enrollment P value 
 2001-2004 2005-2009 2010-2012 2013-2014  
Younger Adolescents n (%) 
n=153 
n (%) 
n=1672 
n (%) 
n=1074 
n (%) 
n=342  
Female sex 72 (47.1) 907 (54.3) 607 (56.5) 208 (60.8) 0.003 
Receipt of PCP prophylaxis  127 (83.0) 1527 (91.3) 1041 (96.9) 336 (98.3) <0.0001 
Receipt of isoniazid for TB prophylaxis 16 (10.5) 81 (4.8) 24 (2.2) 9 (2.6) <0.0001 
CD4 at enrollment, median (IQR) 188 (52 - 444) 262 (93 - 471) 307 (117 - 550) 379 (144 - 662) <0.0001 
CD4 at ART initiation, median (IQR) 140 (33 - 329) 172 (56 - 298) 221 (74 - 385) 233 (73 - 479) <0.0001 
WHO stage at enrollment*      
  Stage 1 and 2 41 (26.8) 722 (43.2) 472 (44) 85 (24.9) -- 
  Stage 3 and 4 49 (32.0) 466 (27.9) 243 (22.6) 17 (5.0) -- 
  Missing 63 (41.2) 484 (29.0) 359 (33.4) 240 (70.2) -- 
WHO stage at ART initiation*†      
  Stage 1 and 2 21 (14.4) 432 (32.7) 341 (39.5) 48 (20.6) -- 
  Stage 3 and 4 82 (56.2) 603 (45.7) 281 (32.6) 15 (6.4) -- 
  Missing 43 (29.5) 285 (21.6) 241 (27.9) 170 (73.0) -- 
Older Adolescents n (%) 
n=82 
n (%) 
n=1234 
n (%) 
n=1069 
n (%) 
n=718  
Female sex 58 (70.7) 959 (77.7) 857 (80.2) 594 (82.7) 0.0013 
Receipt of PCP prophylaxis  46 (56.1) 907 (73.5) 1021 (95.5) 717 (99.9) <0.0001 
Receipt of isoniazid for TB prophylaxis 24 (29.3) 124 (10.1) 34 (3.2) 26 (3.6) <0.0001 
CD4 at enrollment, median (IQR) 225 (25 - 520) 322 (134 - 529) 398 (178 - 612) 427 (261 - 646) <0.0001 
CD4 at ART initiation, median (IQR) 64 (13 - 246) 153 (57 - 258) 219 (63 - 358) 323 (157 - 480) <0.0001 
WHO stage at enrollment*      
  Stage 1 and 2 35 (42.7) 643 (52.1) 611 (57.2) 468 (65.2) -- 
  Stage 3 and 4 17 (20.7) 234 (19.0) 136 (12.7) 82 (11.4) -- 
  Missing 30 (36.6) 357 (28.9) 322 (30.1) 168 (23.4) -- 
WHO stage at ART initiation*†      
  Stage 1 and 2 18 (28.6) 303 (42.7) 340 (49.9) 300 (59.5) -- 
  Stage 3 and 4 24 (38.1) 246 (34.7) 183 (26.8) 84 (16.7) -- 
  Missing 21 (33.3) 160 (22.6) 159 (23.3) 120 (23.8) -- 
Total Adolescents n (%) 
n=235 
n (%) 
n=2906 
n (%) 
n=2143 
n (%) 
n=1060  
Female sex 130 (55.3) 1866 (64.2) 1464 (68.3) 802 (75.7) <0.0001 
Receipt of PCP prophylaxis  202 (86.0) 2618 (90.1) 2096 (97.8) 1057 (99.7) <0.0001 
Receipt of isoniazid for TB prophylaxis 47 (20.0) 238 (8.2) 69 (3.2) 37 (3.5) <0.0001 
CD4 at enrollment, median (IQR) 197 (45 - 444) 281 (105 - 491) 352 (143 - 588) 419 (207 - 652) <0.0001 
CD4 at ART initiation, median (IQR) 126 (20 - 320) 164 (56 - 280) 221 (71 - 371) 309 (124 - 480) <0.0001 
WHO stage at enrollment*      
  Stage 1 and 2 76 (32.3) 1365 (47.0) 1083 (50.5) 553 (52.2) -- 
  Stage 3 and 4 66 (28.1) 700 (24.1) 379 (17.7) 99 (9.3) -- 
  Missing 93 (39.6) 841 (28.9) 681 (31.8) 408 (38.5) -- 
WHO stage at ART initiation*†      
  Stage 1 and 2 39 (18.7) 735 (36.2) 681 (44.1) 348 (47.2) -- 
  Stage 3 and 4 106 (50.7) 849 (41.8) 464 (30.0) 99 (13.4) -- 
  Missing 64 (30.6) 445 (21.9) 400 (25.9) 290 (39.4) -- 
ART, antiretroviral therapy; PCP, pneumocystis pneumonia; TB, tuberculosis; WHO, World Health Organization 
*
 Statistical tests of significance were not performed for WHO stages given the high proportions of missing data. 
† Percentages expressed among total number of adolescents who initiated ART (n=4,520). 
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Table 3. Attrition after enrollment and after ART initiation for younger, older and all adolescents enrolling at 
study facilities in Kenya, Tanzania, and Uganda from 2001-2014. 
 
Age Group Period of Enrollment P value* 
 2001-2004 2005-2009 2010-2012 2013-2014  
 % (95% CI) % (95% CI) % (95% CI) % (95% CI)  
Attrition at 12 months after enrollment  
  Younger Adolescents 2.6 (0.9-6.2) 12.1 (10.6-13.8) 9.9 (8.2-11.8) 8.7 (5.9-12.1) <0.001 
  Older Adolescents 8.5 (3.7-15.9) 25.4 (23.0-27.8) 21.5 (19.1-24.0) 13.6 (11.0-16.4) <0.001 
  Total Adolescents 4.7 (2.5-7.9) 17.7 (16.4-19.2) 15.7 (14.1-17.3) 12.0 (10.1-14.2) <0.001 
  P value† 0.041 <0.001 <0.001 0.076  
Attrition rate at 12 months after ART initiation   
  Younger Adolescents 15.1 (9.8-21.4) 15.4 (13.5-17.4) 19.8 (17.2-22.6) 25.3 (18.8-32.3) <0.001 
  Older Adolescents 27.0 (16.7-38.4) 24.5 (21.4-27.7) 31.8 (28.2-35.4) 34.3 (28.7-40.0)   0.016 
  Total Adolescents 18.7 (13.7-24.2) 18.6 (16.9-20.3) 25.1 (22.9-27.3) 31.2 (26.9-35.6) <0.001 
  P value† 0.035 <0.001 <0.001 0.124  
ART, antiretroviral therapy 
* Compares the cumulative incidence curves by enrollment periods within adolescent age groups. 
† Compares the cumulative incidence curves by adolescent age groups within enrollment periods using the Gray test. 
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